Literature DB >> 21851490

Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia.

A Hagerman1, K M Posfay-Barbe, S Grillet, M M Ochs, R H Brookes, D Greenberg, N Givon-Lavi, R Dagan, C-A Siegrist.   

Abstract

Pneumococcal surface proteins (PSPs) elicit antibody responses in infants and young children exposed to Streptococcus pneumoniae. These seroresponses could contribute to the aetiological diagnosis of pneumococcal disease, e.g. during the clinical development of novel PSP-based vaccines. In this study, we assessed the kinetics of antibody responses to three highly conserved and immunogenic PSPs (pneumococcal histidine triad D (PhtD), pneumococcal choline-binding protein A (PcpA), and serine proteinase precursor A (PrtA)) in 106 children (median age, 21.3 months; males, 58.5%) admitted for pneumococcal bacteraemia. Anti-PhtD, anti-PcpA and anti-PrtA antibodies were measured by ELISA, and compared in 61 pairs of acute (≤7 days) and convalescent (>14 days of admission) serum samples. Acute serum titres were similar to those observed in healthy children, and were unaffected by the acid dissociation of circulating immune complexes. Despite proven bacteraemia, seroresponses (≥2-fold increase in anti-PSP antibody concentrations) were only identified in 31 of 61 children (50.8%), directed against PrtA (n = 23, 37.7%), PcpA (n = 19, 31.1%), and PhtD (n = 16, 26.2%), or several PSPs (two PSPs, n = 13, 21.3%; three PSPs, n = 7, 11.5%). Certain seroresponses were very strong (maximal fold-increases: PhtD, 26; PcpA, 72; PrtA, 12). However, anti-PSP antibody concentrations failed to increase in the convalescent sera of 30 of 61 (49.2%) bacteraemic children, and even declined (≥2 fold) in 13 of 61 (21.3%), mostly infants aged <6 months (8/13, 61.5%), possibly through consumption of maternal antibodies. Thus, pneumococcal bacteraemia may fail to elicit antibody responses, and may even have an antibody-depleting effect in infants. This novel observation identifies an important limitation of serology-based studies for the identification of bacteraemic children.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21851490     DOI: 10.1111/j.1469-0691.2011.03629.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.

Authors:  David Verhoeven; Sheldon Perry; Michael E Pichichero
Journal:  Clin Vaccine Immunol       Date:  2014-05-21

2.  Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.

Authors:  Johan Berglund; Peter Vink; Fernanda Tavares Da Silva; Pascal Lestrate; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

3.  A Pneumococcal Protein Array as a Platform to Discover Serodiagnostic Antigens Against Infection.

Authors:  Alfonso Olaya-Abril; Irene Jiménez-Munguía; Lidia Gómez-Gascón; Ignacio Obando; Manuel J Rodríguez-Ortega
Journal:  Mol Cell Proteomics       Date:  2015-07-16       Impact factor: 5.911

4.  Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data.

Authors:  Marc Lipsitch; Lucy M Li; Scott Patterson; James Trammel; Christine Juergens; William C Gruber; Daniel A Scott; Ron Dagan
Journal:  Vaccine       Date:  2017-12-14       Impact factor: 3.641

5.  Prevalence and clonal distribution of pcpA, psrP and Pilus-1 among pediatric isolates of Streptococcus pneumoniae.

Authors:  Laura Selva; Pilar Ciruela; Krystle Blanchette; Eva del Amo; Roman Pallares; Carlos J Orihuela; Carmen Muñoz-Almagro
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

6.  Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults.

Authors:  Alfonso Olaya-Abril; Irene Jiménez-Munguía; Lidia Gómez-Gascón; Ignacio Obando; Manuel J Rodríguez-Ortega
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

7.  PrtA immunization fails to protect against pulmonary and invasive infection by Streptococcus pneumoniae.

Authors:  Chen-Fang Hsu; Chen-Hao Hsiao; Shun-Fu Tseng; Jian-Ru Chen; Yu-Jou Liao; Sy-Jou Chen; Chin-Sheng Lin; Huey-Kang Sytwu; Yi-Ping Chuang
Journal:  Respir Res       Date:  2018-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.